Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) saw its shares on the rise again this week following an incredibly positive U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) vote. The company announced that the FDA’s PDAC voted 12 to two that the benefits of Nuplazid (pimavanserin) for the treatment of Parkinson’s disease psychosis (PDP) outweigh the risks of treatment.
Previously, 24/7 Wall St. pointed out how Merrill Lynch sees Acadia growing another 60%, in relation to this study.
The Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the Nuplazid New Drug Application (NDA) is May 1. The FDA has granted the Nuplazid NDA Priority Review status and designated Nuplazid for the treatment of psychosis associated with Parkinson’s disease as a Breakthrough Therapy.
About one million people in the United States and around four to six million people worldwide suffer from Parkinson’s disease. An estimated 40% of these patients have PDP, which is characterized by hallucinations and delusions, a diminished quality of life and significant caregiver burden.
Steve Davis, president and CEO of Acadia, commented:
We are very encouraged by the Committee’s positive vote today and look forward to working with the FDA as it completes its review of Nuplazid. If approved by the FDA, Nuplazid would be the first drug indicated to treat psychosis associated with Parkinson’s disease.
Shares of Acadia closed Tuesday up 17% at $23.81, with a consensus analyst price target of $44.80 and a 52-week trading range of $16.64 to $51.99. Following the release of this vote, the stock jumped another 24% to $29.60 in early trading indications on Wednesday.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
